High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis: Table. 1—

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

2003 • 1,933 citations

Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis

2003 • 816 citations

Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis

1996 • 380 citations

Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial

2002 • 202 citations

Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

2002 • 124 citations

Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis

2003 • 83 citations

Asymptomatic Hepatitis in Persons Who Received Alternative Preventive Therapy with Pyrazinamide and Ofloxacin

1997 • 75 citations

Antituberculosis drugs and hepatotoxicity

2004 • 59 citations

Preventive Therapy for Contacts of Multidrug-Resistant Tuberculosis

1994 • 51 citations

Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection

2003 • 41 citations